Syndax Pharmaceuticals Inc — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Goldan Keith A. | Chief Financial Officer | Gift | 1,224 | — | — | Dec 1, 2025 |
| Metzger Michael A | Chief Executive Officer | Option Exercise | 157,307 | $10.90 | $1,714,646 | Sep 8, 2025 |
| Podlesak Dennis | — | Option Exercise | 19,200 | $7.20 | $138,240 | Aug 18, 2025 |
| Goldan Keith A. | Chief Financial Officer | Other | 1,226 | $8.43 | $10,335 | Jul 31, 2025 |
| Goldan Keith A. | Chief Financial Officer | Sale | 1,296 | $9.29 | $12,040 | Jul 16, 2025 |
| Metzger Michael A | Chief Executive Officer | Sale | 7,534 | $9.29 | $69,991 | Jul 16, 2025 |
| Goldan Keith A. | Chief Financial Officer | Purchase | 3,000 | — | — | May 19, 2025 |
| Huber Martin H. Jr. | — | Purchase | 5,000 | $8.99 | $44,950 | May 19, 2025 |
| Katkin Keith | — | Purchase | 10,000 | $9.11 | $91,100 | May 19, 2025 |
| Botwood Nicholas A.J. | Head of R&D, CMO | Purchase | 11,765 | $9.00 | $105,885 | May 16, 2025 |
| Metzger Michael A | Chief Executive Officer | Option Exercise | 6,074 | $7.20 | $43,733 | Mar 14, 2025 |
| Metzger Michael A | Chief Executive Officer | Option Exercise | 7,814 | $7.20 | $56,261 | Mar 4, 2025 |
| Goldan Keith A. | Chief Financial Officer | Sale | 3,777 | $15.50 | $58,544 | Feb 10, 2025 |
| Metzger Michael A | Chief Executive Officer | Sale | 13,288 | $15.50 | $205,964 | Feb 10, 2025 |
| Gallagher Neil | President, Head of R&D | Sale | 4,618 | $15.50 | $71,579 | Feb 10, 2025 |
| Gallagher Neil | President, Head of R&D | Award / Grant | 18,500 | — | — | Feb 5, 2025 |
| Goldan Keith A. | Chief Financial Officer | Award / Grant | 23,400 | — | — | Feb 5, 2025 |
| Metzger Michael A | Chief Executive Officer | Award / Grant | 60,500 | — | — | Feb 5, 2025 |
| Podlesak Dennis | — | Award / Grant | 50,000 | — | — | Feb 5, 2025 |
| Rizo Aleksandra | — | Award / Grant | 25,000 | — | — | Feb 5, 2025 |
| Meury William | — | Award / Grant | 25,000 | — | — | Feb 5, 2025 |
| Katkin Keith | — | Award / Grant | 25,000 | — | — | Feb 5, 2025 |
| Jarrett Jennifer | — | Award / Grant | 25,000 | — | — | Feb 5, 2025 |
| Huber Martin H. Jr. | — | Award / Grant | 25,000 | — | — | Feb 5, 2025 |
| Legault Pierre | — | Award / Grant | 25,000 | — | — | Feb 5, 2025 |
| Goldan Keith A. | Chief Financial Officer | Purchase | 1,250 | $20.03 | $25,038 | Jun 14, 2024 |
| Metzger Michael A | Chief Executive Officer | Award / Grant | 39,000 | — | — | Feb 7, 2024 |
| Goldan Keith A. | Chief Financial Officer | Award / Grant | 35,000 | — | — | Feb 7, 2024 |
| Gallagher Neil | President, Head of R&D | Award / Grant | 13,125 | — | — | Feb 7, 2024 |
| Huber Martin H. Jr. | — | Award / Grant | 17,000 | — | — | Feb 7, 2024 |
| Jarrett Jennifer | — | Award / Grant | 17,000 | — | — | Feb 7, 2024 |
| Katkin Keith | — | Award / Grant | 17,000 | — | — | Feb 7, 2024 |
| Meury William | — | Award / Grant | 17,000 | — | — | Feb 7, 2024 |
| Morrison Briggs | — | Award / Grant | 17,000 | — | — | Feb 7, 2024 |
| Podlesak Dennis | — | Award / Grant | 34,000 | — | — | Feb 7, 2024 |
| Legault Pierre | — | Award / Grant | 17,000 | — | — | Feb 7, 2024 |
| Morrison Briggs | — | Option Exercise | 52,855 | $8.77 | $463,538 | Aug 9, 2023 |
| Meury William | — | Sale | 35,000 | $20.46 | $716,100 | Aug 2, 2023 |
| Morrison Briggs | — | Option Exercise | 52,855 | $8.77 | $463,538 | Jul 10, 2023 |
| Goldan Keith A. | Chief Financial Officer | Sale | 577 | $22.31 | $12,873 | Jun 13, 2023 |
| Morrison Briggs | — | Option Exercise | 28,273 | $8.77 | $247,954 | Jun 9, 2023 |
| Morrison Briggs | — | Sale | 52,855 | $21.41 | $1,131,626 | May 9, 2023 |
| Morrison Briggs | — | Sale | 52,855 | $19.53 | $1,032,258 | Apr 10, 2023 |
| Morrison Briggs | President, Head of R&D | Option Exercise | 52,854 | $6.38 | $337,209 | Mar 13, 2023 |
| Ordentlich Peter | Chief Scientific Officer | Sale | 17,428 | $25.84 | $450,340 | Feb 15, 2023 |
| Metzger Michael A | Chief Executive Officer | Option Exercise | 5,959 | $6.38 | $38,018 | Feb 6, 2023 |
| Morrison Briggs | President, Head of R&D | Sale | 52,854 | $26.83 | $1,418,073 | Feb 6, 2023 |
| Podlesak Dennis | — | Award / Grant | 32,000 | — | — | Feb 2, 2023 |
| Huber Martin H. Jr. | — | Award / Grant | 16,000 | — | — | Feb 2, 2023 |
| Meury William | — | Award / Grant | 16,000 | — | — | Feb 2, 2023 |